The biopharmaceutical company Sorrento Therapeutics reports positive trial results utilizing Sofusa Lymphatic Delivery of the biological medical product Etanercept after completing its first phase 1b human proof of concept study.
The presentation will be held at the EIPBN conference - 65th International Conference on Electron, Ion and Photon Beam Technology and Nanofabrication,
which will take place between May 31 and June 3, 2022, in New Orleans, Louisiana.
Do you enjoy an international work environment and seek to drive change? Are you passionate about nanotechnology, sales, engineering and consider yourself to be a contributing team player? Check out our job opportunities below.
The Sofusa® Drug Delivery System, for which Sorrento Therapeutics use Obducat’s NIL technology to fabricate the nanotopography draped microneedles, was highlighted in Sorrento Therapeutics proprietary mRNA vaccine development program for COVID-19.
Sorrento Therapeutics, a biopharmaceutical company, reports positive initial result in dosing with the Sofusa® Lymphatic Drug Delivery Device. Sorrento Therapeutics use Obducat’s NIL technology to fabricate the nanotopography draped microneedles used in the Sofusa® Drug Delivery System.
Vladislav Genevskiy, who is an Industrial PhD student investigates how different surface or topography patterns induced through Nanoimprint lithography may promote or inhibit the bacteria from growing.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.